Edogestrone
Clinical data
Other namesEdogesterone; PH-218; 17α-Acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one
Drug classProgestogen; Progestogen ester
Identifiers
  • [(8'R,9'S,10'R,13'S,14'S,17'R)-17'-acetyl-6',10',13'-trimethylspiro[1,3-dioxolane-2,3'-2,4,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-17'-yl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC26H38O5
Molar mass430.585 g·mol−1
3D model (JSmol)
  • CC1=C2CC3(CCC2(C4CCC5(C(C4C1)CCC5(C(=O)C)OC(=O)C)C)C)OCCO3
  • InChI=1S/C26H38O5/c1-16-14-19-20(23(4)10-11-25(15-22(16)23)29-12-13-30-25)6-8-24(5)21(19)7-9-26(24,17(2)27)31-18(3)28/h19-21H,6-15H2,1-5H3/t19-,20+,21+,23-,24+,26+/m1/s1
  • Key:UOYMGHSCINLOBK-ZKKYLISVSA-N

Edogestrone (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) (developmental code name PH-218), or edogesterone, also known as 17α-acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one, is a steroidal progestin and antiandrogen of the 17α-hydroxyprogesterone group which was synthesized in 1964 but was never marketed.[1][2] Similarly to the structurally related steroid cyproterone acetate, edogestrone binds directly to the androgen receptor and antagonizes it, displacing androgens like testosterone from the receptor, though not as potently as cyproterone acetate.[3] The drug has also been found to suppress androgen production, likely via progesterone receptor activation-mediated antigonadotropic activity.[4]

See also

References

  1. ↑ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 478–. ISBN 978-1-4757-2085-3.
  2. ↑ Geller J, McCoy K (February 1974). "Biologic and biochemical effects of anti-androgens on rat ventral prostate". Acta Endocrinologica. 75 (2): 385–397. doi:10.1530/acta.0.0750385. PMID 4406552.
  3. ↑ Spring-Mills E, Hafez ES (1 January 1980). Male accessory sex glands: biology and pathology. Elsevier/North-Holland Biomedical Press. p. 500. ISBN 9780444801678.
  4. ↑ Castro JE (9 March 2013). The Treatment of Prostatic Hypertrophy and Neoplasia. Springer Science & Business Media. pp. 39–. ISBN 978-94-015-7190-6. Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin, Chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.